TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT04301336
Drug: Zinc sulfate
Normalized name: Zinc Sulfate
DrugBank: Zinc acetate (DB14487)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 50 patients from each participating hospital that will receive Zinc supplements (15 mg to 50 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study: NCT04301336
Drug: Statins (Cardiovascular Agents)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50 patients from each participating hospital that will receive Simvastatin orally (20 mg to 40 mg ) per day for 8 consecutive months up to 10 months.~in addition to the experimental treatment, this group will receive the traditional treatment of hydroxyurea, Folic acid, pain killer plus regular blood transfusion with a dose de-escalation methods till efficacy of experimental treatment proved.
Study: NCT04301336
Drug: Folic Acid Supplementation
Normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Folic Acid dose of 0.5 to 1 mg daily for 3 to 4 weeks until definite hematologic response
Study: NCT01670656
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Ibuprofen 400 mg will be dispensed throughout the entire study as needed as rescue medication for treating menstrual cramping pain. The maximum daily ibuprofen dose is 3200 mg (8 tablets)
Study: NCT03986008
Drug: Benaglutide
Approvals — FDA: no, EMA: no, PMDA: no
Description: The treatment of Benaglutide lasted three months.During the first week: 0.1mg per day;During the second week: 0.14mg per day; From third week onwards, 0.2mg per day.
Study: NCT01715805
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dose-matched placebo capsule once per day
Study: NCT01715805
Drug: Antidepressant Therapy (ADT)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: ADT such as bupropion, citalopram, desvenlafaxine, duloxetine, escitalopram, fluoxetine, sertraline, venlafaxine, paroxetine or vilazodone as prescribed by the physician.
Study: NCT02904304
Drug: Desloratadine+Phenylephrine+Ibuprofen
Normalized name: Desloratadine
DrugBank: Desloratadine (DB00967)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 01 tablet, orally, every 12 hours.
Study: NCT02904304
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 01 tablet, orally, every 12 hours.
Study: NCT03315000
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Same as placebo arm description
Study: NCT01049425
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 4 cycles, intravenous infusion, day 1 every three weeks
Study: NCT01049425
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 6 cycles, intravenous infusion, day 1 every 3 weeks
Study: NCT00385931
Drug: Valsartan and simvastatin
Normalized name: simvastatin and ezetimibe
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03199625
Drug: SSRI antidepressants
Normalized name: ANTIDEPRESSANTS
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02324933
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fentanyl Patient Controlled Analgesia for post-operative pain management
Study: NCT00137033
Drug: Celecoxib
Normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00137033
Drug: Naproxen
Normalized name: Naproxen
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT02741960
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg placebo three times daily
Study: NCT03332524
Drug: SP160412 Ibuprofen 400 mg and Chlorpheniramine maleate 4 mg
Normalized name: ibuprofen 400 MG
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 2 Ibuprofen and capsules Chlorpheniramine maleate 3 time per day for 72 hours
Study: NCT03332524
Drug: 2 capsules Ibuprofen and 1 placebo
Normalized name: PLACEBO CAP/TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ibuprofen and placebo
Study: NCT00637221
Drug: NPL-2009
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single doses of either 50mg, 100 mg or 150 mg NPL-2009
Study: NCT03104634
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo and delivery device matched to active intervention
Study: NCT01558622
Drug: dexketoprofen trometamol
Normalized name: Dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50mg intravenous infusion
Study: NCT01558622
Drug: dexketoprofen trometamol + tramadol hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 50mg dexketoprofen trometamol + 100mg tramadol hydrochloride
Study: NCT01558622
Drug: dexketoprofen trometamol + pethidine hydrochloride
Normalized name: dexketoprofen trometamol
Approvals — FDA: no, EMA: no, PMDA: no
Description: intravenous infusion of 50mg dexketoprofen trometamol + 50mg pethidine hydrochloride
Study: NCT02512575
Drug: AZD9567 Monohydrat
Normalized name: Lactose Monohydrate
Approvals — FDA: no, EMA: no, PMDA: no
Description: AZD9567 oral suspension 0.5 to 10 mg/ml
Study: NCT02512575
Drug: Placebo oral suspension/ Placebo capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Matching placebo
Study: NCT02512575
Drug: Prednisolone
Normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Prednisolone 60mg oral capsules (12 capsules of 5 mg each).
Study: NCT03152552
Drug: LIK066
Approvals — FDA: no, EMA: no, PMDA: no
Description: LIK066 was supplied in different doses as tablets taken orally.
Study: NCT03152552
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo was supplied as tablets and capsules taken orally.
Study: NCT00160433
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, oral Daily for 12 weeks
Study: NCT00758953
Drug: Placebo Once Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi-solid
Study: NCT00758953
Drug: Placebo Twice Weekly
Approvals — FDA: no, EMA: no, PMDA: no
Description: semi-solid
Study: NCT02983734
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sugar pill
Study: NCT01517698
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to RO4917523 orally once a day for 12 weeks
Study: NCT01517698
Drug: RO4917523 0.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mg orally once a day for 12 weeks
Study: NCT01517698
Drug: RO4917523 1.5 mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1.5 mg orally once a day for 12 weeks
Study: NCT03151434
Drug: US Guided Paravertebral Catheter (0.2% ropivicaine bolus)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Paravertebral catheter will be placed under ultrasound guidance at the thoracic region prior to surgery.
Study: NCT03829904
Drug: VGH-BPH1
Approvals — FDA: no, EMA: no, PMDA: no
Description: A scientific Chinese granule powder
Study: NCT00427050
Drug: PEP005
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT04111445
Drug: ADG116
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV infusion at Day 1 of each cycle
Study: NCT01233791
Drug: Placebo Suppository
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will be asked to use one vaginal suppository every night for 28 days
Study: NCT00060450
Drug: nitric oxide for inhalation
Normalized name: nitric oxide Inhalant Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Either 10 or 20 ppm of inhaled nitric oxide for 24 hour post transplant
Study: NCT00060450
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo gas will be given at 10 or 20 ppm for 24 hours post transplant
Study: NCT00615966
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose, IV
Study: NCT03926091
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Cyclophosphamide chemotherapy (injection)
Study: NCT01558154
Drug: Chinese herbs
Approvals — FDA: no, EMA: no, PMDA: no
Description: Chinese herbs special for depression
Study: NCT01453595
Drug: BEZ235
Approvals — FDA: no, EMA: no, PMDA: no
Description: BEZ235 will be taken orally twice daily starting on Day 1, Cycle 1, self-administration will continue twice daily on a continuous schedule with cycle length defined as 28 days. Increasing dosing levels of BEZ235 will be studied sequentially (beginning with Dose Level 1, BEZ235 400mg by mouth twice daily) as per the treatment noted below.~Cohort-1a BEZ235 300 mg by mouth twice daily Cohort 1 BEZ235 400 mg by mouth twice daily Cohort 2 BEZ235 600 mg by mouth twice daily Cohort 3 BEZ235 800 mg by mouth twice daily
Study: NCT00052468
Drug: TCG
Normalized name: TCGF
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT00052468
Drug: TC
Normalized name: PTC
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT03077724
Drug: Placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olive Oil capsules
Study: NCT03204097
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral prophylaxis followed by placement of placebo gel
Study: NCT00755989
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: topical gel without morphine
Study: NCT01318226
Drug: ATx08-001
Approvals — FDA: no, EMA: no, PMDA: no
Description: ATx08-001 will be administered as a 6mm white film coated tablet of 2.5 mg strength, to be taken orally at a dose of 2.5 mg or 7.5 mg, twice a day approximately every 12 hours over an 8 day period.
Study: NCT01318226
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered as a 6mm white film coated tablet, twice a day approximately every 12 hours over an 8 day period. Placebo is identical in appearance to the ATx 08-001 tablet.
Study: NCT02621931
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo 1.5 mL pre-filled syringes identical in appearance to active intervention. Study drug was administered at the clinical site.
Study: NCT03312556
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo pill or patch. Single dose
Study: NCT03747926
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: single-rising oral dose
Study: NCT04232423
Drug: Placebo ORAL TABLET
Normalized name: placebo ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: * Placebo 1 tab orally, ondansetron 8 mg intravenously, and dexamethazone 8 mg intravenously 30 minutes before chemotherapeutic administration (day 1)~* Placebo 1 tab orally daily and dexamethazone 8 mg orally daily on day 2, 3, 4
Study: NCT00159211
Drug: UMULINE NPH
Normalized name: humulene
Approvals — FDA: no, EMA: no, PMDA: no
Description: UMULINE NPH at bed time with a increasing dose up to get a fasting glycemia under 1.1 g/l
Study: NCT03719105
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive methotrexate as part of chemoimmunotherapy regemin followed by allogeneic stem cell transplant.
Study: NCT03719105
Drug: pralatraxate,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive pralaxtraxate as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study: NCT03719105
Drug: cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Patients will receive cyclophosphamide as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study: NCT03719105
Drug: Doxorubicin
Normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Patients will receive doxorubicin as part of chemoimmunotherapy regimen followed by allogeneic stem cell transplant.
Study: NCT02486926
Drug: Remifentanil
Normalized name: Remifentanil
DrugBank: Remifentanil (DB00899)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Anesthesia of patients was maintained with both sevoflurane and continuous remifentanil infusion.
Study: NCT00709280
Drug: 7% Hypertonic Saline (HS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study: NCT00709280
Drug: 0.9% Isotonic Saline (IS)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Administered via inhalation twice daily for 48 ± 4 weeks. The delivery system is a PARI Sprint Junior nebulizer with a PARI Baby face mask or mouthpiece driven by a PARI Pro Neb compressor.
Study: NCT04066114
Drug: mycophenolic acid
Normalized name: mycophenolic acid
DrugBank: Mycophenolic acid (DB01024)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: mycophenolic acid is started no later than one day after transplant at 720mg PO twice daily provided WBC count permits, staying on it until everoliumus level is within therapeutic range. Participants that do not tolerate everolimus can stay on or switch back to 720 mg twice daily of mycophenolic acid and remain in trial.
Study: NCT00208793
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT03489616
Drug: Single agent
Approvals — FDA: no, EMA: no, PMDA: no
Description: Other chemotherapy drugs,such as Docetaxel, gemcitabine
Study: NCT04323852
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT00089726
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT01060293
Drug: Low-dose furosemide combined with low-dose dopamine
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose furosemide combined with low-dose dopamine (LDFD): continuous IV administration of 5 mg/h furosemide combined with 5 μg/kg/min dopamine for a total of 8 hours
Study: NCT03731468
Drug: local anesthetic
Normalized name: Local anesthetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: ultrasound guided superficial cervical block in thyroid surgery
Study: NCT00046358
Drug: Lovostatin
Normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
Approvals — FDA: yes, EMA: no, PMDA: no
Study: NCT00046358
Drug: Ibuprofen
Normalized name: Ibuprofen
DrugBank: Ibuprofen (DB01050)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT04184063
Drug: NBMI
Normalized name: N-Benzyl-D-glucamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: NBMI active treatment
Study: NCT02313467
Drug: Topical application of 1.5% Butenyl ALA
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02779153
Drug: Acthar low dose (40 U)
Approvals — FDA: no, EMA: no, PMDA: no
Description: The 40U group will administer 0.5 mL of study medication once a day. Patients will taper study medication during Week 2 through the remainder of the study and will administer 0.5 mL of study medication twice a week. The stable Acthar regimen should be maintained for the remainder of the study. However, dose adjustments may be implemented if needed based on safety.
Study: NCT00463710
Drug: Avonex® monotherapy (6.0 MIU administered i.m. each week)
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02293629
Drug: Placebo matching BMS-986147
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01605617
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PTNS + placebo for 12 weeks
Study: NCT00075738
Drug: fluorouracil
Normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00075738
Drug: leucovorin calcium
Normalized name: Leucovorin Calcium
DrugBank: Leucovorin (DB00650)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT00797797
Drug: No Treatment Added
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: No added treatment
Study: NCT01726413
Drug: GRC 17356
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01726413
Drug: Matching Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT02737735
Drug: standard chemotherapy medicine
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT01695850
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The placebo MZRW is made from dextrin (76.03%), tea essence (23.61%), gardenin (0.02%) and caramel (0.34%) to achieve color, smell, taste and texture comparable to MZRW granules.The placebo Senna is made of starch and colour to achieve comparable appearance to Senokot.
Study: NCT03583372
Drug: placebos
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo to match vibegron (experimental drug) and tolterodine (active comparator)
Study: NCT02769169
Drug: Lucentis® (Raibizumab) double-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 1mg of Lucentis® (Raibizumab). Intervention 'double-dose: Ranibizumab 1mg, 3 injection plus prn' has not been included in any Arm/Group Descriptions.
Study: NCT02769169
Drug: Lucentis® (Raibizumab) regular-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Give patients 1 injection per month at the beginning 3 months. Give patients additional injection as needed. One injection contains 0.5mg of Lucentis® (Raibizumab). regular-dose: Ranibizumab 0.5mg, 3 injection plus prn
Study: NCT04161001
Drug: Amlodipine/Olmesartan 10/40mg (Combination drug), Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-administration of Sevikar tab. 10/40mg(Amlodipine/Olmesartan 10/40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Olmetec Tab. 40mg(Olmesartan 40mg)
Study: NCT04161001
Drug: Olmesartan 40mg, Ezetimibe/Rosuvastatin 10/20mg(Combination drug)
Approvals — FDA: no, EMA: no, PMDA: no
Description: co-administration of Olmetec tab. 40mg(Olmesartan 40mg), Rosuzet Tab. 10/20mg(Ezetimibe/Rosuvastatin 10/20mg) and placebo of Sevikar tab. 10/40mg (Amlodipine/Olmesartan 10/40mg)
Study: NCT00396240
Drug: Rosuvastatin
Normalized name: Rosuvastatin
DrugBank: Rosuvastatin (DB01098)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT02071004
Drug: DS-1040b
Normalized name: Uretron DS
Approvals — FDA: no, EMA: no, PMDA: no
Description: IV of 6 mg given once over 30 minutes
Study: NCT05439460
Drug: Epinephrine
Normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 5 subjects will get Epinephrine during cardiac catheterization in patient with known Pulmonary Arterial Hypertension.Dose will be 0.5-1ug/kg body weight. Pressures in the pulmonary artery will be measured before and after the drug administration.
Study: NCT02854904
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo controlled
Study: NCT00903747
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo (Group 2b)
Study: NCT00315250
Drug: [123I]β-CIT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single Photon Emission Computed Tomography~SPECT imaging uses the single photon emissions from radioactive compounds that are (most commonly) injected into a patient and are metabolized by specific organs or body systems. SPECT imaging is performed by using a gamma camera to acquire multiple 2-D images (also called projections), from multiple angles. A computer is then used to apply a tomographic reconstruction algorithm to the multiple projections, yielding a 3-D dataset. This dataset may then be manipulated to show thin slices along any chosen axis of the body, similar to those obtained from other tomographic techniques, such as MRI, CT, and PET. The resulting SPECT images reflect body/organ function as opposed to specific anatomy of other imaging modalities such as CT or MRI.
Study: NCT03810209
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: adding normal saline to local anaesthetic in SAP block
Study: NCT04416269
Drug: Oral Anti-diabetes Drugs alone
Normalized name: Diabetic Tussin EX Oral Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: OADs will be continued at same outpatient dosage unless contraindicated. Participants will be switched to the preferred drug within the category of medication they take at home. Dose adjustment for OADs will be based on clinical/laboratory status. The OAD will be held if the participant is placed on strict nil per os (NPO) and is unable to take oral medications after enrollment.
Study: NCT03457532
Drug: Gumarontinib Tablets
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg; 50mg; 100mg; 200mg; 400mg; 600mg BID or QD(Decided by SMC accroding to the safty and PK data)
Study: NCT01672801
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral administration
Study: NCT02273141
Drug: NER1006, Day Before-Only Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer both doses of NER1006 in the evening of Day 1 with 1-2 hours interval. Subject will take mandatory additional clear fluid after each dose.
Study: NCT02273141
Drug: SP+MS, Day Before-Only Dosing
Approvals — FDA: no, EMA: no, PMDA: no
Description: The subject will self-administer SP+MS in the morning of Day 1 and afternoon of Day 1. Subject will take mandatory additional clear fluid after each dose.
Study: NCT02774057
Drug: Captafer®
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 pills daily. Contains~* Vitamin C, known for its property to facilitate iron absorption by reducing iron to the reduced ferrous state necessary for uptake;~* Vitamin E, an antioxidant, along with vitamin C it protects Fe++;~* Folic acid, necessary to prevent megaloblastic anemia and abnormalities in the fetal nervous system, vital during pregnancy;~* Zinc and Copper which act in different mitochondrial cytochromes-dependent systems and contribute to the use of iron by the biological systems
Study: NCT02774057
Drug: Iron Sulfate
Normalized name: iron sulfate (1:1)
DrugBank: Iron (DB01592)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 195 mg Iron supplement
Study: NCT01673802
Drug: CT scan
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gadoxetate (Eovist) enhanced dual energy CT
Study: NCT00934466
Drug: MK2637
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 120 mg MK2637 capsules in one of five treatment periods.
Study: NCT00934466
Drug: Comparator: MK2637
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 50 mg MK2637 capsules in one of five treatment periods.
Study: NCT00934466
Drug: Comparator: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of placebo only in one of five treatment periods.
Study: NCT02959437
Drug: INCB057643
Approvals — FDA: no, EMA: no, PMDA: no
Description: INCB057643 will be orally self- administered once daily beginning on Cycle 1 Day 1 and continuously thereafter in 21-day cycles.